SCHEMBL3762707

SCHEMBL3762707

[CH2]CCCN1CCCCC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
CYP1A2 P05177 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
CYP2D6 P10635 1/20 0.42
CHRM1 P11229 1/20 0.42
CYP2C9 P11712 1/20 0.42
CHRM3 P20309 1/20 0.42
CYP2C19 P33261 1/20 0.42
PIK3CD O00329 1/20 0.41
KMT2A Q03164 5/20 0.41
MEN1 O00255 2/20 0.41
PKM P14618 1/20 0.41
RAB9A P51151 2/20 0.40
TSHR P16473 2/20 0.40
ACHE P22303 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ADRA1B P35368 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9730913 0.98 L3MBTL1 (0.46) L3MBTL1CYP1A2CHRM2CHRM4CHRM5
SCHEMBL2323038 0.94 PIK3CD (0.47) CYP1A2CHRM2CHRM4CHRM5CYP2D6
SCHEMBL1219977 0.88 L3MBTL1 (0.46) L3MBTL1CYP1A2CHRM2CHRM4CHRM5
SCHEMBL1935110 0.86 L3MBTL1 (0.49) L3MBTL1CYP1A2CHRM2CHRM4CHRM5
SCHEMBL1446682 0.82 L3MBTL1 (0.44) L3MBTL1CYP1A2CHRM2CHRM4CHRM5
SCHEMBL374573 0.81
SCHEMBL5424673 0.81 PIK3CD (0.54) CYP1A2CHRM2CHRM4CHRM5CYP2D6
SCHEMBL1447142 0.80 L3MBTL1 (0.43) L3MBTL1CYP1A2CHRM2CHRM4CHRM5
SCHEMBL1447146 0.80 TSHR (0.44) L3MBTL1CYP1A2CHRM2CHRM4CHRM5
SCHEMBL1446683 0.80 KMT2A (0.45) L3MBTL1CYP1A2CHRM2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1713465-A4 COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS IRM LLC (BM) 2009-04-22 EP claimed
US-20070293547-A1 Compounds and Compositions as Lxr Modulators IRM LLC (BM) 2007-12-20 US claimed
EP-1713465-A2 COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS IRM LLC (BM) 2006-10-25 EP claimed
WO-2005077122-A2 COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS IRM LLC (BM) 2005-08-25 WO claimed
US-11591426-B2 Copolymer, wetting agent, medical device, and method for producing same TORAY INDUSTRIES, INC. (JP) 2023-02-28 US disclosed
EP-3438144-B1 COPOLYMER, WETTING AGENT, MEDICAL DEVICE, AND METHOD FOR PRODUCING SAME TORAY INDUSTRIES (JP) 2021-06-30 EP disclosed
US-20210015960-A1 COPOLYMER, WETTING AGENT, MEDICAL DEVICE, AND METHOD FOR PRODUCING SAME TORAY INDUSTRIES, INC. (JP) 2021-01-21 US disclosed
US-20190099511-A1 COPOLYMER, WETTING AGENT, MEDICAL DEVICE, AND METHOD FOR PRODUCING SAME TORAY INDUSTRIES, INC. (JP) 2019-04-04 US disclosed
EP-3438144-A1 COPOLYMER, WETTING AGENT, MEDICAL DEVICE, AND METHOD FOR PRODUCING SAME Toray Industries, Inc. (JP) 2019-02-06 EP disclosed
US-7846949-B2 liver X receptors (LXR) modulators such as Tert-butyl 2-(2,4,6-trifluoro-N-(3-hydroxyphenyl benzamido)acetate, useful in the treatment of LXR-associated diseases such as cardiovascular disorders, inflammation and disorders of glucose metabolism such as insulin resistance and obesity IRM LLC (BM) 2010-12-07 US disclosed
EP-1713465-A4 COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS IRM LLC (BM) 2009-04-22 EP disclosed
US-20070293547-A1 Compounds and Compositions as Lxr Modulators IRM LLC (BM) 2007-12-20 US disclosed
EP-1713465-A2 COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS IRM LLC (BM) 2006-10-25 EP disclosed
WO-2005077122-A2 COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS IRM LLC (BM) 2005-08-25 WO disclosed
US-6444677-B2 TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. PFIZER INC. 2002-09-03 US disclosed
EP-1106614-A1 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC. (US) 2001-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293547-A1 Compounds and Compositions as Lxr Modulators NR1H2, NR1H3, NR1H4 L3MBTL1 3357/4885CYP1A2 321/4885CHRM2 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.